Edition:
United States

Takeda Pharmaceutical Co Ltd (TKPYY.PK)

TKPYY.PK on OTC Markets Group

21.86USD
26 May 2016
Change (% chg)

$0.37 (+1.70%)
Prev Close
$21.50
Open
$21.75
Day's High
$21.99
Day's Low
$21.75
Volume
678,998
Avg. Vol
30,557
52-wk High
$26.52
52-wk Low
$21.04

TKPYY.PK

Chart for TKPYY.PK

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)
No analyst recommendations are available for TKPYY.PK.

Overall

No Ratios Available.

Financials

  TKPYY.PK Industry Sector
P/E (TTM): -- 34.15 35.24
EPS (TTM): -- -- --
ROI: -- 14.00 13.33
ROE: -- 15.11 14.57

Valeant rejected joint takeover bid from Takeda, TPG in spring: source

Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP [TPG.UL] this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.

May 26 2016

UPDATE 2-Valeant rejected joint takeover bid from Takeda, TPG in spring - source

May 26 Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.

May 26 2016

BRIEF-Valeant received joint takeover approach from Takeda, TPG before Joseph Papa became CEO - source

* Valeant received joint takeover approach from Takeda, TPG a few weeks before Joseph Papa became CEO - Source Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 26 2016

Valeant rejected joint takeover bid from Takeda, TPG in spring-WSJ

May 26 Valeant Pharmaceuticals International Inc received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that the Canadian drugmaker rejected, the Wall Street Journal reported, citing people familiar with the matter.

May 26 2016

BRIEF-Valeant approached by earlier rejected Takeda, TPG for takeover-CNBC

* Valeant received joint takeover approach from Takeda, TPG that it rejected this spring before hiring new CEO - CNBC, citing DJ

May 26 2016

Hikma wins dismissal of Takeda patent lawsuit over gout drug

A federal court has cleared the way for Hikma Pharmaceuticals Plc to continue selling a drug with the same active chemical as Takeda Pharmaceutical Co's gout drug Colcrys, dismissing a patent lawsuit Takeda filed in an effort to keep the drug off the market.

May 20 2016

Gates Foundation backs Takeda polio vaccine with $38 million grant

LONDON Japan's Takeda Pharmaceuticals is to get $38 million from the Bill & Melinda Gates Foundation to develop a crucial, low-cost polio vaccine for use in developing countries.

May 08 2016

BRIEF-Prosetta Biosciences and Takeda Pharmaceutical enter into agreement

* Co and Takeda Pharmaceutical Co Ltd, enter into agreement to discover and develop novel compounds for neurodegenerative diseases Source text for Eikon: Further company coverage:

May 02 2016

A

May 02 2016

BRIEF-Orexigen says paid $60 mln due under separation agreement with Takeda

* On March 29, 2016 co made initial payment of $60 million due under that certain separation agreement with Takeda Pharmaceutical Co Ltd Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 04 2016

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Sadif Analytics Prime
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.